FDA approves Perrigo’s Topicort Spray generic

SILVER SPRING, Md. — The Food and Drug Administration has approved Perrigo’s generic of Topicort Spray (desoximetasone topical spray, 0.25%), the company announced Tuesday. The companies have settled prior patent litigation on confidential terms. 

 

The drug is indicated to treat plaque psoriasis in patients 18 years of age or older and had sales estimated at $24 million for the 12 months ended November 2016, the company said. 

 

“The ability to develop and bring to market difficult formulations such as this one is what differentiates Perrigo's Rx employees and portfolio and furthers our offerings to customers around the globe,” Perrigo CEO John Hendrickson said.